The Manufacturers Life Insurance Company Grows Position in Monte Rosa Therapeutics, Inc. $GLUE

The Manufacturers Life Insurance Company raised its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 55.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 209,801 shares of the company’s stock after purchasing an additional 75,127 shares during the period. The Manufacturers Life Insurance Company’s holdings in Monte Rosa Therapeutics were worth $3,451,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter valued at $32,000. Lazard Asset Management LLC boosted its holdings in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after acquiring an additional 3,262 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the period. Prudential Financial Inc. acquired a new stake in Monte Rosa Therapeutics during the second quarter worth about $54,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at about $63,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Insiders Place Their Bets

In other news, COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $20.00, for a total transaction of $43,500.00. Following the sale, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at approximately $1,247,420. The trade was a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at approximately $231,100. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 81,778 shares of company stock valued at $1,768,581 over the last ninety days. Insiders own 6.40% of the company’s stock.

Monte Rosa Therapeutics Trading Up 1.1%

NASDAQ GLUE opened at $15.88 on Friday. The stock has a market cap of $1.34 billion, a P/E ratio of -9.02 and a beta of 1.59. The company’s fifty day simple moving average is $20.53 and its 200-day simple moving average is $19.35. Monte Rosa Therapeutics, Inc. has a 52 week low of $4.12 and a 52 week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 48.30%. The firm had revenue of $8.97 million for the quarter, compared to analyst estimates of $12.91 million. On average, research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GLUE. Zacks Research raised shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Company dropped their price objective on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday. Guggenheim cut their target price on shares of Monte Rosa Therapeutics from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. Finally, Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $28.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.